person · Reporting owner
TZOUMAKAS KIMBERLY JO
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Coherus Oncology, Inc.CHRS · Entity 6276 | Director | June 03, 2024 | June 05, 2024 |
| SeaSpine Holdings CorpSPNE · Entity 120832 | Director | June 03, 2020 | June 05, 2020 |
| Starling Oncology, Inc.TOI · Entity 5327 | Director | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Coherus Oncology, Inc.
Report date June 03, 2024 · Filed June 05, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.76 · Expires 2034-06-03 | Direct | 112,000 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 112,000 · Balance 112,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date.
SeaSpine Holdings Corp
Report date June 03, 2020 · Filed June 05, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,670 |
Reported balance
After 2020-06-03 transaction · row 1
1 source rowRow 1 · 2020-06-03 · Grant · Acquired 8,488 · Balance 21,670 F1: The restricted stock award vests in full on June 3, 2021, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock award vests in full on June 3, 2021, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting.
Starling Oncology, Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 46,301 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Grant · Acquired 29,116 · Balance 46,301 F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 22:50 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 29,116 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000985 · ownership.xml · nonDerivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,301 F1 · kind: Represents grant of restricted stock units (RSUs), each of which entitle the Reporting Person to receive one share of the Issuer's common stock upon settlement. The RSUs vest in full on the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting Person's continued service with the Issuer on the vesting date. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 20:30 UTC | Starling Oncology, Inc. TOI · Entity 5327 | GrantCommon Stock | 17,185 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-26-000940 · ownership.xml · nonDerivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,185 F1 · kind: Represents RSU award that was fully vested upon grant Read SEC document |
| June 03, 2024 Filed Jun 5, 2024 22:46 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 112,000 | $0.00 Strike: $1.76 | $0.00 |
DisclosureSEC source: 0001610717-24-000287 · form4.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,000 Underlying: Common Stock · 112,000 shares Expires 2034-06-03 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the one year anniversary of June 3, 2024, subject to Reporting Person's continued service relationship with the Issuer on such vesting date. Read SEC document |
| June 07, 2023 Filed Jun 9, 2023 20:59 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 38,250 | $0.00 Strike: $5.38 | $0.00 |
DisclosureSEC source: 0001610717-23-000119 · form4.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,250 Underlying: Common Stock · 38,250 shares Expires 2033-06-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from June 7, 2023, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 07, 2022 Filed Jan 10, 2022 21:31 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $15.94 | $0.00 |
DisclosureSEC source: 0001567619-22-000923 · doc1.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-01-07 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 07, 2022 Filed Feb 11, 2022 21:12 UTC Amendment | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $14.67 | $0.00 |
DisclosureSEC source: 0001567619-22-003505 · doc1.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2032-01-07 F1 · derivative.exercise_price: The Form 4/A is being filed solely to correct a typographical error in the exercise price. Except as noted in this footnote, all other information as disclosed in the Reporting Person's original Form 4 was accurately reported. F2 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2022, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| January 11, 2021 Filed Jan 13, 2021 21:27 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $17.58 | $0.00 |
DisclosureSEC source: 0001567619-21-000986 · doc1.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-01-11 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/12th of the total number of shares subject to the option in successive, equal monthly installments measured from January 1, 2021, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| July 30, 2020 Filed Aug 3, 2020 21:43 UTC | Coherus Oncology, Inc. CHRS · Entity 6276 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $18.15 | $0.00 |
DisclosureSEC source: 0001567619-20-014073 · doc1.xml · derivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2030-07-30 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 1/36th of the total number of shares subject to the option in successive, equal monthly installments measured from July 30, 2020, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date. Read SEC document |
| June 03, 2020 Filed Jun 5, 2020 21:40 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 8,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-20-000079 · wf-form4_159140758661500.xml · nonDerivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,670 F1 · shares: The restricted stock award vests in full on June 3, 2021, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| May 29, 2019 Filed May 31, 2019 16:13 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 7,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-19-000077 · wf-form4_155933358739141.xml · nonDerivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,182 F1 · shares: The restricted stock award vests in full on May 29, 2020, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation ("SeaSpine") at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
| February 19, 2019 Filed Feb 20, 2019 17:54 UTC | SeaSpine Holdings Corp SPNE · Entity 120832 | GrantCommon Stock | 5,920 | $0.00 | $0.00 |
DisclosureSEC source: 0001637761-19-000028 · wf-form4_155070326945881.xml · nonDerivative · entry 1 TZOUMAKAS KIMBERLY JO · CIK 0001766666 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,920 F1 · shares: The restricted stock award vests in full on February 19, 2020, subject to the Reporting Person not experiencing a termination of service prior to such date. In addition, if the Reporting Person stands for reelection to the board of directors of SeaSpine Holdings Corporation at an annual meeting of stockholders but is not reelected to the board at such annual meeting, the award will vest in full on the date of such annual meeting. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.